Results 191 to 200 of about 154,631 (333)

Imatinib Induced Tumor Lysis Syndrome in a Patient with Gastrointestinal Stromal Tumor

, 2015
Hatim Karachiwala, Bruce Colwell
openalex   +2 more sources

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Treatment of Tumor Lysis Syndrome in a pediatric patient with a reported higher serum uric acid level [PDF]

Lia Bittencourt, Patrícia Martins, Alexander Becker, Zeni Klem, Emannuely Izidoro   +4 more
openalex   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

, 2011
Kristie A. Blum, A. S. Ruppert, Jennifer A. Woyach, Jeffrey A. Jones, Leslie A. Andritsos, Joseph M. Flynn, Brad H. Rovin, Miguel A. Villalona‐Calero, JI Jun-sheng, Mitch A. Phelps, Amy J. Johnson, Michael R. Grever, John C. Byrd   +12 more
openalex   +2 more sources

Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy [PDF]

, 2014
Mahmood Rasool, Arif Malik, Muhammad Saeed Qureshi, Riaz Ahmad, Abdul Manan, Muhammad Asif, Muhammad Imran Naseer, Peter Natesan Pushparaj   +7 more
openalex   +1 more source

IRF4 Enhances Radiosensitivity of Cervical Cancer by Inhibiting the PI3K/Akt/mTOR Pathway to Regulate Autophagy

Cancer Science, EarlyView.
IRF4 is a prognostic biomarker in cervical cancer. IRF4 enhances radiosensitivity and inhibits tumor growth via PI3K/AKT/mTOR‐mediated autophagy. IRF4 boosts radiation response in vitro and in vivo. ABSTRACT Interferon regulatory factor 4 (IRF4), a critical member of the IRF transcription factor family, harbors an elusive biological role in cervical ...
Meihui Gao, Zhaolei Cui, Huachun Song, Yanhong Li, Anyang Li, Jianfeng Zheng, Linying Liu, Xuefen Lin, Wankai Fu, Yang Sun   +9 more
wiley   +1 more source

Infection Masquerading As Spontaneous Tumor Lysis Syndrome. [PDF]

Cureus, 2023
DeSalvo J, Rossetti AL.
europepmc   +1 more source

HHV-8-ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE IN AN HIV CARRIER COMPLICATED BY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND TUMOR LYSIS SYNDROME: ATYPICAL PRESENTATIONS IN A RARE LYMPHOPROLIFERATIVE DISORDER

, 2023
JVR Oliveira, MRF Dória, AO Lauar, CWA Cano, GOA Barbosa, JCKD Santos, CW Erthal, MW Araujo, LAPC Lage, Jorge Pereira   +9 more
openalex   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source